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Abstract
Background: Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual
health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11,
and half of episodes diagnosed are recurrences. The best and most cost-effective treatment for patients with
anogenital warts is unknown. The commonly used treatments are self-administered topical agents, podophyllotoxin
(0.15% cream) or imiquimod (5% cream), or cryotherapy with liquid nitrogen. Quadrivalent HPV (qHPV) vaccination
is effective in preventing infection, and disease, but whether it has any therapeutic effect is not known.
Methods and design: To investigate the efficacy of clearance and prevention of recurrence of external anogenital
warts by topical treatments, podophyllotoxin 0.15% cream or imiquimod 5% cream, in combination with a three-
dose regimen of qHPV or control vaccination. 500 adult patients presenting with external anogenital warts with
either a first or subsequent episode of anogenital warts will be entered into this randomised, controlled partially
blinded 2 × 2 factorial trial.
Discussion: The trial is expected to provide the first high-quality evidence of the comparative efficacy and
cost-effectiveness of the two topical treatments in current use, as well as investigate the potential benefit of HPV
vaccination, in the management of anogenital warts.
Trial registration: The trial was registered prior to starting recruitment under the following reference numbers:
International Standard Randomized Controlled Trial Number (ISRCTN) Registry - ISRCTN32729817 (registered 25
July 2014); European Union Clinical Trials Register (EudraCT) - 2013-002951-14 (registered 26 June 2013).
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Background
The most effective and cost-effective treatment for pa-
tients with anogenital warts is unknown. Genital warts
are benign lesions which present as lumps or raised pla-
ques in the skin of the anogenital area. Usually painless,
but occasionally causing irritation or bleeding, they can
be emotionally distressing, and often require prolonged,
time consuming and uncomfortable treatment. Relapse
after apparently successful treatment occurs frequently.
Surgery may be required in persistent cases. About 90%
of genital warts are caused by human papillomavirus
(HPV) types 6 or 11, which are sexually transmitted.
There were 122,068 episodes of new or recurrent
genital warts treated in sexual health services in
England in 2016 [1], of which 49% were recurrent
episodes. First episode genital warts accounted for
15% of new sexually transmitted infections (STIs) di-
agnosed, making it the second most common condi-
tion after chlamydia. The cost to the NHS of treating
anogenital warts in 2016 is estimated at almost £14
million per year, of which about £6 million is for re-
current episodes [2].
Cryotherapy with liquid nitrogen is frequently used to
treat anogenital warts, although this treatment requires
equipment and facilities usually only available in hos-
pital or specialist community settings, and appropri-
ately trained staff. Effective treatment may be achieved
with a single application, but more often requires re-
peated clinic attendance. Consequently, most cases of
warts are now treated with self-administered topical
agents, of which podophyllotoxin is the most common
[3]. Podophyllotoxin has a chemotherapeutic action be-
lieved to be based on prevention of tubulin polymerisa-
tion required for microtubule assembly and inhibition
of nucleoside transport through the cell membrane,
leading to inhibition of growth of virally infected cells.
It is available as a solution or a cream and has been
studied in a number of randomised trials [3–11]. The
cream (Warticon®, Glaxo SmithKline) includes the ac-
tive agent at a lower concentration than the solution
(0.15% versus 0.5%) but is generally considered to be
easier to apply, better tolerated, and have similar effi-
cacy. An alternative topical treatment is imiquimod,
but this is more expensive, so usually reserved for
second-line therapy. Imiquimod is available as a 5%
cream (Aldara®, Meda). Some studies have suggested
that imiquimod is associated with less recurrence as a
result of its mode of action as an immune response
modifier [12, 13]. It is a toll-like receptor 7 agonist, and
stimulates tissue macrophages to release interferon-alpha
and other cytokines which trigger a local cell-mediated re-
sponse. Imiquimod has no direct antiviral activity. The
treatment response may be slower than podophyllotoxin.
It is licensed for a treatment duration of up to 16 weeks;
most patients will have responded by 8 weeks. The
efficacy has been investigated in a number of trials
[11, 14–21].
The efficacies of podophyllotoxin and imiquimod as
initial therapy for anogenital warts have never been
compared in an adequately-powered trial [22]. The only
randomised trial comparing the two topical agents was
under-powered (n = 51) and did not report recurrence
rates [11]. There were similar clearance rates (75% vs.
72%, 95% confidence interval 53–98% and 52–86% re-
spectively). A systematic review of wart treatment
undertaken for the European guidelines for the treat-
ment of genital warts [22], suggested that podophyllo-
toxin has a similar rate of initial clearance (43–70% at
4 weeks, compared to 55–81% clearance at 16 weeks for
imiquimod), but recurrence rates may be lower with imi-
quimod (6–26% at 6 months for imiquimod, compared
to 6–55% at 8–12 weeks for podophyllotoxin). The wide
variation between reported studies is also likely related
to differences in study design, including the outcome
measures and timing. The review found no evidence of
any single therapy being superior overall, largely due to
the lack of high-quality comparative studies, with those
reported being heterogeneous in design, and with high
loss to follow-up. Until this comparison is resolved in
randomised studies of sufficient size and robust design it
remains impossible to firmly recommend one treatment
over the other. UK national guidelines recommend that
the choice of first line therapy be based on patient pref-
erence and morphology and distribution of lesions, with
a clinic treatment algorithm to guide treatment [23].
It is not known whether the clearance or recurrence
rate of anogenital warts can be improved by vaccination
against HPV 6 and 11, initiated at the same time as top-
ical therapy. HPV vaccines are currently licensed to pre-
vent HPV-associated anogenital warts and cancers;
quadrivalent HPV vaccine (qHPV; Gardasil®, Merck
Sharp & Dohme) protects against genotypes 6, 11, 16
and 18, and from September 2012 has been the vaccine
used in the national vaccination programme in the UK
for girls aged 12–13 years. The potential role of the vac-
cine as therapy or secondary prevention for anogenital
warts (or indeed any HPV-associated disease) has yet to
be determined. While no randomised controlled trial
(RCT) evidence exists, evidence that vaccination against
HPV may offer a therapeutic or secondary preventative
strategy comes from several sources. Firstly, there are
case reports that clearance of anogenital warts may be
enhanced by qHPV vaccine [24, 25]. Secondly, patients
with anogenital warts or genital intraepithelial neoplasia
(cervical [CIN], vulval [VIN] or vaginal [VaIN]) are at
risk of re-infection with the same or different HPV
types, or relapse of existing infection [26, 27]. Thirdly,
limited evidence from placebo-controlled vaccine trials
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appears to show that women who are HPV seropositive,
but DNA-negative for at least one HPV type at trial
entry were protected against subsequent disease related
to the HPV type to which they were previously exposed
[28]. Also, women with genital lesions treated surgically
while in the vaccine trial were less likely to develop re-
current or progressive disease if they were in the vaccine
arm of the trial [29]. Fourthly, preliminary evidence sug-
gests that the qHPV vaccine may reduce recurrences of
respiratory papillomatosis (RRP) in children [30], and of
anal intraepithelial neoplasia (AIN) [31], both conditions
caused by vaccine-type HPVs. Finally, vaccine antibody
responses are much stronger than those induced by nat-
ural infection [32], so a strategy of priming or boosting
anti-HPV 6/11 responses with qHPV vaccine could in-
fluence the persistence of HPV 6/11 infection and there-
fore the rate of disease recurrence.
Studies of the treatment cost and quality of life impact
of genital warts, as well as economic analyses of vaccin-
ating against warts have been conducted [2, 33, 34].
These studies have documented significant negative im-
pacts on quality of life and substantial health care ser-
vice costs. The cost of imiquimod remains higher than
that of podophyllotoxin. If the effectiveness of imiqui-
mod proves superior, then an economic analysis would
allow an assessment of the maximum cost difference
that would warrant its use as first line therapy. All avail-
able treatments have significant failure and recurrence
rates. By maximising initial response rates and reducing
recurrence rates using first-line self-administered treat-
ment, a randomised controlled trial has the capacity to
reduce this health and quality of life burden for patients
and improve cost effectiveness, now and in the future.
Vaccination would add to the cost of treatment of pa-
tients with anogenital warts. If efficacy is demonstrated,
then an economic analysis could determine at what level
the increased treatment costs would be justified by re-
duced future healthcare costs and improved quality of
life related to persistent or recurrent disease.
The proposed trial will assess the comparative efficacy
of the two main topical treatments in current use, podo-
phyllotoxin 0.15% cream and imiquimod 5% cream, and
will investigate the potential therapeutic benefit of the
qHPV vaccine in the management of patients with ano-
genital warts. The trial will also evaluate the relative costs
of the two topical treatments, as well as of the novel use
of qHPV vaccination for both treatment and secondary
prevention. The adoption of a pragmatic trial design with
broad entry criteria for the comparison of the two topical
therapies means that the results can be generalised to the
large number of health care settings where anogenital
warts are treated. The topical therapies assessed and the
potential (within the protocol) to use supplementary cryo-
therapy are closely aligned with current clinical practice.
Methods
Study design
The study is a randomised, controlled partially blinded
2 × 2 factorial design trial for the treatment of anogenital
warts, with an accompanying economic analysis. Partici-
pants are allocated in equal numbers to all four combi-
nations of the two topical treatments and two vaccines
(Table 1). Analysis of the primary outcome will be based
on logistic regression.
Study setting
The trial is run at selected sexual health clinics in England
and Wales (see Additional file 1: Participating sites); about
80% of cases of genital warts treated in the NHS are
treated in sexual health clinics.
Study population
Those eligible to participate are adults aged 18 or over
presenting to participating sexual health clinics with ex-
ternal anogenital warts which, in the opinion of the in-
vestigator, could be appropriately treated with either
self-administered imiquimod or podophyllotoxin cream.
Patients with either first episode or repeat episode ano-
genital warts are eligible.
The main exclusion criteria are those who have had
treatment for warts in the past 3 months, and those who
have previous qHPV vaccine; previous bivalent HPV vac-
cine is not an exclusion. Other exclusion criteria relate
to contraindications to any of the products, including
Table 1 Interventions received according to the 2 × 2 factorial trial design. Randomisation is 1:1 between the two topical cream
arms and 1:1 for qHPV and placebo
Topical creams
Imiquimod Podophyllotoxin
Vaccines qHPV vaccine Arm A
n = 125
Imiquimod cream for 16 weeks;
qHPV vaccine at months 0, 2 and 6
Arm B
n = 125
Podophyllotoxin cream for 4 weeks;
qHPV vaccine at months 0, 2 and 6
Saline, placebo control Arm C
n = 125
Imiquimod cream for 16 weeks;
placebo vaccine at months 0, 2 and 6
Arm D
n = 125
Podophyllotoxin cream for 4 weeks;
placebo vaccine at months 0, 2 and 6.
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previous intolerance, pregnancy, lactation, and a total
wart area in excess of 4 cm2, which would require treat-
ment under medical supervision. Patients requiring top-
ical steroids applied to the affected area, or on systemic
immunosuppressive agents were also excluded.
Initially, participants with known HIV infection were
excluded but in December 2015 the entry criteria were
modified to allow their inclusion. The change in criteria
allows the inclusion of the majority of HIV-positive indi-
viduals, but still excludes those with more severe im-
munosuppression, who may be less likely to respond to
topical treatment or to HPV vaccine. Current evidence is
that those HIV-positive individuals stable on antiretro-
viral treatment with a CD4 count above 350, and those
not on treatment with CD4 count above 500, mount
good responses to vaccines, and have similar responses
to treatment for some other chronic viral infections,
such as hepatitis C [35–37]. It was concluded that HIV-
positive individuals fulfilling these criteria should not be
excluded. This would allow an estimated 80% of HIV-
positive patients with warts to be eligible. It would also
be of benefit to observe if the response to the trial inter-
ventions was comparable in those with and without HIV
infection, although it is acknowledged that the power to
detect any such effect would be limited. As a precaution,
HIV status was added as a stratification variable.
Interventions
Topical treatment (for up to 16 weeks)
Imiquimod Participants randomised to imiquimod are
asked to apply the 5% cream for three days of the week
(every other day). The cream should be applied at the
participant’s bed time and left on overnight. The cream
should be washed off after 6–10 h.
Podophyllotoxin Participants randomised to podophyl-
lotoxin are instructed to apply the 0.15% cream to the
lesions twice a day for three consecutive days followed
by no treatment for 4 days, in weekly cycles. The li-
censed treatment duration is 4 weeks, but it is common
practice to extend this period if there is a partial re-
sponse to therapy.
Vaccine treatment
qHPV vaccine Quadrivalent HPV vaccine, Gardasil –
Sanofi Pasteur MSD, given according to the licenced
schedule at 0, 2, and 6 months; vaccine volume 0.5 ml;
containing alum adjuvant.
Placebo 0.5 ml normal saline injection as control.
Participants are randomised to one of 4 groups (Table 1):
A. imiquimod cream plus qHPV vaccine;
B. podophyllotoxin cream plus qHPV vaccine;
C. imiquimod cream plus saline placebo injection.
D. podophyllotoxin cream plus saline placebo
injection.
Allocation to the groups is carried out using minimisa-
tion with a random element, with gender, previous oc-
currence of warts, and trial site as stratification factors.
HIV status was added as a stratification factor when the
entry criteria were changed. Participant identifiers and
trial arm allocation are computer generated using a se-
cure on-line service, which requires entry of limited par-
ticipant characteristics.
Topical creams are dispensed in unblinded packaging
and vaccine treatment is dispensed in blinded packaging
using vaccine codes. The vaccinations are administered
by trained members of the clinic staff, who are not part
of the trial team involved in trial assessments.
Screening and baseline assessment
After assessing eligibility and obtaining written informed
consent, information on the following is collected: the
date of first presentation; dates of previous episodes, and
treatment of warts; history of sexually transmitted infec-
tions and co-morbidities; history of recent sexual con-
tacts; concomitant medication; and quality of life
questionnaire. Baseline assessment includes examination
of the anogenital area and documentation of the position
and approximate number of warts (in categories: 1–5,
6–10, 11–20, > 20). The maximum diameter of the lar-
gest wart is recorded, measured against a size gauge. A
symptom-directed general physical examination is per-
formed if appropriate. A blood sample (for serum) and a
swab of the lesions (for HPV DNA) are taken and
stored, for future methodological studies. Randomised
treatments are prescribed or administered and partici-
pants are supplied with information on their use, risks
and side-effects. Participants are offered safer sex advice,
and access to other sexual and reproductive health ser-
vices as per routine care. For women of child bearing
potential a pregnancy test is performed. Simple diary
cards are provided for the participant to use as a re-
minder of when the treatment should be applied, record
its use, record if, and when, warts have cleared and rec-
ord symptom scores related to the topical treatment.
Follow-up assessments
Routine follow up is for 48 weeks in total, with visits at
4, 8, 16, 24 and 48 weeks (see Table 2). Further topical
treatment is issued according to the randomisation/re-
assessment at weeks 4 and 8. Vaccine is administered at
weeks 8 and 24.
Presence of warts is determined on examination by a
member of the trial clinical team at each study visit to
confirm clearance/recurrence. Participants are asked to
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return to the clinic early if they notice a recurrence so
that this can be documented (and the date of recurrence
recorded) and further treatment offered according to
standard of care. If warts recur within the first 16 weeks
the participant is prescribed the treatment that they
were randomised to at baseline.
Cryotherapy should only be administered from 4 weeks
(visit 2) onwards if in the opinion of the investigator this
is in the best interests of the patient and after assessment
of the response to topical treatment to date. Careful con-
sideration should be given to delaying cryotherapy beyond
4 weeks where a response to topical treatment is observed
in the interest of preserving the integrity of the rando-
mised comparison. If a participant is unable to tolerate the
allocated treatment, after dose modifications as appropri-
ate, alternative treatment can be administered at the dis-
cretion of the investigator. For the purposes of the trial,
early use (within 4 weeks of the start of randomised treat-
ment) of alternative treatments and topical treatment
switch to the opposite arm before 16 weeks is considered
a topical treatment failure. Participants should continue to
be followed up and receive vaccinations as per protocol.
Table 2 Baseline and follow up assessments and procedures
Visit number 1 2 3 4 5 6 Extra visits if
warts recurWeek 0
(baseline)
4
(± 1 week)
8
(± 2 weeks)
16
(± 3 weeks)
24
(± 3 weeks)
48
(± 5 weeks)
Give Participant Information Sheet
and go through trial with participant
X
Check eligibility, complete and sign
Consent Form
X
Randomisation X
Record wart treatment X X X X X X X
Review and record concomitant medication X X X X X X X
Examine and record approximate
number and location of warts/the
absence of warts
X X X X X X X
Symptom-directed general
examination
X
Urine pregnancy test (βhCG) (women
of child bearing potential onlya)
X Xa Xa Xa Xa Xa Xa
Quality of life questionnaire (EuroQoL
EQ-5D-5 L)
X X X X X X X
Assessment of tolerability X X X X X
Assessment of Adverse Events and
Pregnancy
X X X X X X
Assessment of treatment response
and need for additional/altered
treatment
X X X X X X
Lesion swab for HPV detection
(all participants, samples to be
archived)
X X
Blood sample (all participants, serum
sample to be archived)
X X
Supply trial wart treatment X X X
Supply/apply additional/alternative
wart treatment if required and as
permitted in the protocol
X X X X X X (from week
4 onwards)
Vaccination X X X
Provide diary card for self-treatment
and self-examination record
X X X X X
Collect/review diary card X X X X X X
Completion/review of electronic
trial documentation
X X X X X X X
aPregnancy test to be completed, if the participant has not adhered to using effective contraception and is being prescribed any trial topical treatment. Effective
contraception defined per HMA CTFG guidance (see Additional file 2: Effective contraception)
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After week 16, topical treatment can be changed at the
discretion of the investigator, including a switch to the
other randomised topical treatment. Timing of eventual
wart clearance is recorded for the secondary outcome
(time to clearance).
Participants are provided with a diary card to record
treatments applied and the date the warts are last seen
and/or recur, and if there are additional visits between
week 16 and 48 for clinical care, a record of presence/
absence of warts is made.
Routine visits include an assessment of treatment re-
sponse, as reported by the participant, and observed by
the clinician, adherence to the treatment regimen, toler-
ability, health-related quality of life, and the need for
additional or extended treatment. Participants are also
asked about work days lost due to clinic visits. Diary
cards are collected. An end of trial blood sample is col-
lected at week 48, and a lesion swab, to be stored for
later HPV DNA detection is collected in the event of
wart recurrence. Additional visits are arranged in the
event of recurrences or other indications for additional
treatment or review in line with routine clinical practice,
or if significant adverse events occur that require med-
ical assessment. In order to reduce the loss to follow-up
rate, a small financial incentive is provided to those par-
ticipants who attend the week 16 and week 48 visits.
Primary outcome
A composite endpoint of wart clearance 16 weeks after
starting treatment and remaining wart-free between 16
and 48 weeks. This captures both the initial clearance ef-
ficacy as well as the impact on relapse or recurrence.
Secondary outcomes
The two components of the composite primary endpoint
are considered as factor specific clinically important sec-
ondary outcomes:
a) for topical treatment– proportion wart-free at
16 weeks.
b) for vaccination– proportion remaining wart free
between week 16 and week 48 in those with wart
clearance at 16 weeks.
Other secondary outcomes are:
1. Proportion wart-free at the end of the assigned
treatment course (4 or 16 weeks)
2. Proportion wart-free at the end of the assigned
treatment course (4 or 16 weeks) without receiving
additional treatment
3. Quantity of additional treatment (number of
cryotherapy applications, additional weeks of
podophyllotoxin or imiquimod) required to achieve
clearance by 16 weeks
4. Proportion wart-free at 16 weeks without receiving
additional treatment
5. Proportion experiencing complete wart clearance
6. Proportion experiencing wart recurrence/relapse
after complete wart clearance
7. Time to complete wart clearance
8. Time from complete wart clearance to recurrence/
relapse
9. Adverse events
10. Health-related quality of life, as measured by the
Area Under the Curve for EQ-5D-5 L
11. Symptom scores
12. Total costs of treatment including prescribed agents
and clinic visits
Statistical considerations
Sample size
The trial was originally designed with a sample size of
1000 participants with equal numbers randomised to
each of the two topical cream arms and each of the two
vaccine groups in a 2 × 2 factorial design, so that allow-
ing for 20% loss to follow-up 800 participants would
contribute primary outcome data. The anticipated pro-
portion achieving the primary endpoint in the less
favourable topical treatment group was 35%, assuming a
wart clearance rate of 50% within 16 weeks and a 30%
subsequent recurrence rate. This sample size provided
80% power (at the 5% significance level) to detect an in-
crease to 45% with the better treatment. It also provided
80% power to detect an increase from 35 to 45% in the
primary endpoint from vaccination, as would arise if
vaccination reduces the recurrence rate from 30 to 10%
whilst leaving the wart clearance rate unchanged at 50%.
Owing to a lack of feasibility to achieve the proposed
recruitment target of 1000, a revised sample size of 500
participants was proposed in February 2016. With 15%
loss to follow-up, this would provide 52% power (at the
5% significance level) to detect the pre-specified differ-
ence in the combined primary endpoint.
It was expected that the main effect of the topical
treatment would be on wart clearance, and the main ef-
fect of vaccination would be on wart recurrence. The
power of the study to detect a clinically important differ-
ence in each of these secondary outcomes was therefore
calculated in proposing the reduced trial size.
The revised sample size will provide 80% power at the
5% significance level, assuming 15% loss to follow up, to
evaluate each of the two components of the primary out-
come: 1) Proportion wart-free at 16 weeks; 2) Proportion
remaining wart-free at 48 weeks among participants who
are wart-free at 16 weeks. For the 16 week topical treat-
ment outcome, a difference of 14% between topical arms
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(57% versus 43%) could be detected; for the 48 week
vaccine outcome, a difference of 16% between vaccine
arms (12% versus 28%) could be detected. These differ-
ences are considered to be clinically important and may
influence management guidelines. A 5% significance
level has been used for both calculations as there is a
different outcome for each of the two factors to answer
two independent questions.
Statistical methods
Analysis will be by intention-to-treat (where participants
are analysed according to the treatment arm to which
they were randomised), and will include all participants
for whom an outcome is obtained. The primary analysis
for both factors (podophyllotoxin vs. imiquimod, and
qHPV vs. placebo vaccine) will be based on comparisons
at the margins of the 2 × 2 table (Table 1), meaning all par-
ticipants randomised to podophyllotoxin will be compared
with all participants randomised to imiquimod, and all
participants randomised to qHPV vaccine will be com-
pared with all participants randomised to saline placebo.
We do not anticipate a substantial interaction between
topical treatment and vaccination. However, as a second-
ary analysis, we will perform an interaction test between
the two factors, and present results from a four-arm
analysis (where each of the four treatment groups is
regarded as a separate treatment arm), as is recom-
mended for factorial trials [38, 39].
The primary outcome (the composite endpoint of wart
clearance 16 weeks after starting treatment and re-
maining wart-free between 16 and 48 weeks) and its two
components (wart clearance at 16 weeks, and no wart
recurrence by 48 weeks in those with wart clearance at
16 weeks) will be analysed using a logistic regression
model, and will be adjusted for gender, previous occur-
rence of warts, HIV status and site as stratification fac-
tors [40, 41], and will include both treatment factors
(topical treatment and vaccination) as covariates. Treat-
ment effect estimates, 95% confidence intervals, and
two-sided p-values will be reported for each outcome
measure. Multiple imputation using chained equations
[42] will be used to impute data for missing follow-up
visits; the imputation model and number of imputations
will be fully specified in the statistical analysis plan. Par-
ticipants who do not attend any follow-up visits will be
excluded from the analysis. A detailed statistical analysis
plan will be written prior to final analysis and will in-
clude the planned analyses for the primary outcome
and all secondary outcomes, subgroup analyses and
sensitivity analyses.
Economic evaluations
Economic outcomes will be collected in the same way as
previous studies by the investigators [33]. Health-related
quality of life will be assessed using the EuroQol EQ-
5D-5 L. Information on types of treatments given and num-
ber of visits made will be collected. These will be combined
with unit costs from standard NHS sources as well as costs
and treatment patterns from a previous economic study
[33] to evaluate treatment costs. As the previous study was
conducted in 2009–10, a panel of clinicians will be con-
sulted to see if typical treatment patterns have changed
since that time. Clinical, quality of life and cost data will be
used to assess the relative cost-effectiveness of alterna-
tive treatment options, with or without vaccination.
Cost-effectiveness analyses will be conducted according
to the reference case used by the National Institute for
Health and Care Excellence to ensure comparability
with other economic evaluations.
Discussion
Anogenital warts are the second most common sexually
transmitted infection seen in patients presenting to sex-
ual health services in the UK. Although benign, they can
cause troublesome symptoms and distress. Treatment
can be slow, time-consuming and uncomfortable, and
recurrence is common. Since 2012, the HPV vaccine
programme in 12–13 year-old girls has used the quadri-
valent vaccine which is effective against HPV 6 and 11,
in addition to the high-risk HPV16/18 types which cause
most genital cancer. While the incidence of anogenital
warts in young adults is beginning to fall, the current
programme is not predicted to result in elimination and
effective treatment for warts will continue to be re-
quired. The best first line topical treatment for anogeni-
tal warts has not been established in clinical trials, so
that treatment guidelines lack a firm basis for their rec-
ommendations. The HPV vaccine is indicated to prevent
infection; a therapeutic effect, although suggested, has
not been established in a clinical trial.
The trial design is pragmatic, intended to allow as
wide a range of participants as possible, to enable the re-
sults to be generalised. Both patients with a first presen-
tation of warts, and those with a previous history are
included. Those with warts that have been treated re-
cently (within the last 3 months) are excluded, on the
grounds that we are not investigating the efficacy in
warts resistant to standard treatment.
The study does not have a placebo topical treatment
arm to be able to detect an effect of vaccine on clearance
in the absence of any topical treatment. While of scien-
tific interest, this would have increased the size of the
study, and make it harder to recruit given the current
standard of care.
No change of topical treatment before 16 weeks is
allowed as this is the primary endpoint for the topical
treatment effect, even though the licensed duration of
treatment differs for the two products. The addition of
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cryotherapy after week 4 is permitted because of current
practice in the UK. A failure of response after 4 weeks of
podophyllotoxin, which is the licensed duration of treat-
ment, would currently prompt consideration of alterna-
tive treatment. In order to retain participants in the
study, continuation of podophyllotoxin up to 16 weeks
is therefore permitted within the protocol. Use of cryo-
therapy after 4 weeks is at the discretion of the investiga-
tor; cryotherapy use is recorded. A cryotherapy-alone arm
was not included as being beyond the remit of this study,
and because of the implications for the size of the trial.
Two limitations arose during the implementation of
the study. It was intended that the vaccine would be
blinded, with matching syringes containing a saline pla-
cebo. However, the vaccine is supplied in a bespoke
pre-filled syringe and we were unable to source un-filled
syringes to make a matching placebo. In order to min-
imise the risk of un-blinding, the vaccine is supplied in
an opaque, sealed pouch contained within an outer car-
ton. The vaccine or placebo is administered by a health
care worker who is not involved in participant recruit-
ment or follow up assessments, under instructions to
avoid showing the vaccine syringe to either the partici-
pant or the trial team.
The study was designed with a sample size of 1000
participants. However, identifying trial sites in the UK
with the resources and infrastructure to recruit partici-
pants proved to be very difficult. In order to complete
the trial within the agreed timelines set by the funder,
even with a no-cost extension, it was agreed that a re-
duced sample size would have to be accepted. The trial
will therefore be underpowered for the combined pri-
mary endpoint. However, the power will be better for
the two most important secondary endpoints, the rate of
clearance at week 16 and the rate of recurrence at week
48, in those who have cleared warts by week 16.
The trial will provide the first high-quality evidence of
the comparative efficacy of the two main topical treat-
ments in current use, as well as the first randomised trial
to investigate the potential therapeutic benefit of an
HPV vaccine in the management of patients with ano-
genital warts.
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